Skip to main content

Table 3 Univariate analyses of various clinical parameters in prostate cancer patients

From: Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer

Parameters

Progression-Free Survival

Cancer-Specific Survival

Overall Survival

HR (95% CI)

P-value

HR (95% CI) P-value

HR (95% CI)

P-value

Age (years)

0.969 (0.948–0.990)

0.004

0.971 (0.944–1.000)

0.050

0.988 (0.962–1.015)

0.396

PSA (μg/L)

1.000 (1.000–1.001)

0.228

1.000 (1.000–1.001)

0.273

1.000 (0.999–1.001)

0.611

Gleason Score

 

< 0.001

 

< 0.001

 

< 0.001

  ≤ 7

1

 

1

 

1

 

  > 7

2.907 (2.006–4.211)

 

6.425 (3.265–12.643)

 

4.740 (2.733–8.220)

Metastasis

 

< 0.001

 

< 0.001

 

< 0.001

 No

1

 

1

 

1

 

 Yes

3.528 (2.443–5.096)

 

7.920 (4.024–15.589)

 

4.122 (2.496–6.809)

 

Risk Stratification

 

0.023

 

0.069

 

0.095

 Lowintermediate

1

 

1

 

1

 

 High

2.428 (1.133–5.205)

24.120 (0.779–746.903)

 

2.357 (0.861–6.447)

PNI

 

0.004

 

0.001

 

< 0.001

  < 50.2

1

 

1

 

1

  ≥ 50.2

0.590 (0.414–0.841)

 

0.391 (0.226–0.676)

 

0.407 (0.250–0.662)

 
  1. Abbreviations: HR Hazard ratio; CI Confidence interval; PSA Prostate-specific antigen; PNI Prognostic nutritional index